Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought unde…
Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type of blood cancer. The studies were led by Adam Kittai, MD, Associate Professor of Medicine (Hematology and Medical Oncology) at t…
In the fight against cancer, immunotherapy—which aims to boost the body’s natural defenses against cancer—is experiencing remarkable growth. Most of these treatments are based on CD8 T lymphocytes, “killer cells” able to eliminate diseased cells. A tea…
A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery for patients with aggressive stage III non-small cell lung cancer that is considered difficult or impossible to surgically remove…
Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize dysfunctional or “exhausted” immune cells in their fight against cancer.
BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated the muscle layer—is one of the earliest forms of cancer immunotherapy. Now, 50 years after it was first developed from the tuber…
A University of Alberta research team has identified a DNA structure that activates the immune system in cancer cells that are usually resistant to immunotherapy, offering hope of new, more effective treatments for colorectal and other cancers.
Scientists at Nagoya University in Japan studied what happens when macrophages—a type of immune cell—encounter dying cancer cells in tumors and discovered a mechanism that accelerates tumor growth. When cancer cells begin to die within tumors, they exp…
The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus immunotherapy, when added to paclitaxel chemotherapy, both …
Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor worldwide. CRC refers to cancer in the colon or rectum, the two parts that make up the large intestine. In the US, deaths from…
